Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 8, 2003, Pages 2487-2491

  Kuhn F ^a   Cottagnoud, M ^a   Acosta, F ^a   Flatz, L ^a   Entenza, J ^b   Cottagnoud, P ^b,c  

^a Spital Bern Ziegler ^*  (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GENE PRODUCT; LEVOFLOXACIN; PROTEIN PARC; PROTEIN PARE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; GENE MUTATION; GENETIC CODE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-INFECTIVE AGENTS; CEFOTAXIME; CEPHALOSPORINS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; MENINGITIS, PNEUMOCOCCAL; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN; PENICILLIN RESISTANCE; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STREPTOCOCCUS PNEUMONIAE;

EID: 18544391446     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.8.2487-2491.2003     Document Type: Article

References (27)

1. Belohradsky, B. H., K. Bruch, D. Geiss, D. Kafetzis, W. Marget, and G. Peters. 1980. Intravenous cefotaxime in children with bacterial meningitis. Lancet 12:61-63.
2. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canada surveillance network. N. Engl. J. Med. 341:233-239.
3. Cottagnoud, P., F. Acosta, M. Cottagnoud, K. Neftel, and M. G. Täuber. 2000. Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. Antimicrob. Agents Chemother. 44:2179-2181.
4. Cottagnoud, P., J. M. Entenza, M. Cottagnoud, Y.-A. Que, P. Moreillon, and M. G. Täuber. 2001. Sub-inhibitory concentrations of vancomycin prevent quinolone-resistance in a penicillin-resistance isolate of Streptococcus pneumoniae. BMC Microbiol. 1:1-9.
5. Cottagnoud, P., C. M. Gerber, M. Cottagnoud, and M. G. Täuber. 2002. Gentamicin increases the efficacy of vancomycin against penicillin-resistant pneumococci in the meningitis model. Antimicrob. Agents Chemother. 46: 188-190.
6. Dacey, R. G., and M. A. Sande. 1974. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob. Agents Chemother. 6:437-441.
7. Davidson, R., R. Cavalcanti, J. L. Brunton, D. J. Bast, J. C. de Azavedo, P. Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumoniae. N. Engl. J. Med. 346: 747-750.
8. Eliopoulos, G. M., and R. C. Moellering. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
9. Entenza, J. M., U. Flückiger, P. M. Glauser, and P. Moreillon. 1997. Levofloxacin versus ciprofioxacin, flucloxacillin or vancomycin for treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci. Antimicrob. Agents Chemother. 41:1662-1667.
10. Gerber, C. M., M. Cottagnoud, K. A. Neftel, M. G. Täuber, and P. Cottagnoud. 2000. Evaluation of cefepime alone and in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. J. Antimicrob. Chemother. 45:63-68.
11. Gootz, T. D., R. Zaniewski, S. Haskell, B. Schmieder, J. Tankovic, D. Girard, P. Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (CP-99219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40:2691-2697.
12. Jacobs, M. R. 1999. Drug-resistant Streptococcus pneumoniae: rational antibiotic choices. Am. J. Med. 106(Suppl.):19-25.
13. Kaplan, S. L., and E. O. Mason. 1998. Management of infections due to antibiotic-resistant Streprococcus pneumoniae. Clin. Microbiol. Rev. 11:628-644.
14. Lack, S., and R. D. Hotchkiss. 1960. A study of genetic material determining an enzyme activity in pneumococcus. Biochem. Biophys. Acta 39:508-518.
15. Landesman, S. H., P. M. Schah, M. Armengaud, M. Barza, and C. E. Cherubin. 1981. Past and current roles for cephalosporin antibiotics in treatment of meningitis. Am. J. Med. 71:693-703.
16. McCullers, J. A., B. K. English, and R. Novak. 2000. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J. Infect. Dis. 181:369-373.
17. Munoz, R., and A. G. de la Campa. 1996. parC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperated with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
18. Nau, R., M. Kaye, E. Sachdeva, M. Sande, and M. G. Täuber. 1994. Rifampin for the therapy of experimental pneumococcal meningitis in rabbits. Antimicrob. Agents Chemother. 38:1186-1189.
19. Nau, R., T. Schmidt, K. Kaye, J. L. Froula, and M. G. Täuber. 1995. Quinolone antibiotics in therapy of experimental meningitis in rabbits. Antimicrob. Agents Chemother. 39:593-597.
20. Niedermann, M. S., L. A. Mandell, A. Anzueto, J. B. Bass, W. A. Broughton, D. G. Campbell, N. Dean, T. File, M. File, P. A. Gross, F. Martinez, T. J. Marrie, J. F. Plouffe, J. Ramirez, G. A. Sarosi, A. Torres, R. Wilson, and V. L. Yu. 2001. Guidelines for the management of adults with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 163:1730-1754.
21. Pan, W. S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
22. Pan, X. S., and L. M. Fisher. 1996. Cloning and characterization of the parC and pare genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178:4060-4069.
23. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
24. Scotton, P. G., F. Pea, M. Giobbia, M. Baraldo, A. Vaglia, and M. Furlanut. 2001. Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis. Clin. Infect. Dis. 33:109-111.
25. Simon, H. J., and E. Y. Yin. 1970. Microassay of antimicrobial agents. Appl. Microbiol. 19:573-579.
26. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streprococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510.
27. Täuber, M. G., C. J. Hackbarth, K. G. Scott, M. G. Rusnak, and M. A. Sande. 1985. New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits. Antimicrob. Agents Chemother. 27:340-342.